‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine

References

• Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust. 2018 May 21;208(9):404–409.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018 Aug;33(8):1248–1266. .
   PubMed Web of Science ®Google Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180–198. .
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Personalized medicine in Parkinson’s disease: time to be precise. Mov Disord. 2017 Aug;32(8):1147–1154.
   PubMed Web of Science ®Google Scholar
• Левин О. Лечение болезни Паркинсона на ранней стадии. В мире лекарств. 2001;1:41–47.
   Google Scholar
• Kurlan R. “Levodopa phobia”: a new iatrogenic cause of disability in Parkinson disease. Neurology. 2005 Mar 8;64(5):923–924.
   PubMed Web of Science ®Google Scholar
• Titova N, Levin O, Katunina E, et al. ‘Levodopa Phobia’: a review of a not uncommon and consequential phenomenon. NPJ Parkinsons Dis. 2018;4:31.
   PubMed Web of Science ®Google Scholar
• Espay AJ, Lang AE. Common myths in the use of levodopa in Parkinson disease: when clinical trials misinform clinical practice. JAMA Neurol. 2017 Jun 1;74(6):633–634.
   PubMed Web of Science ®Google Scholar
• Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014 Sep 27;384(9949):1196–1205.
   PubMed Web of Science ®Google Scholar
• Weiss HD, Marsh L. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract. 2012 Dec;2(4):267–274.
   PubMedGoogle Scholar
• Poewe W, Antonini A, Zijlmans JC, et al. Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging. 2010 Sep;7(5):229–238.
   Google Scholar
• RMA DB, Clarke CE, Espay AJ, et al. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol. 2020 May;19(5):452–461. .
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009 May;8(5):464–474. .
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017 Jul;18(7):435–450.
   PubMed Web of Science ®Google Scholar
• Lang AE, Lees A. Management of Parkinson’s disease: an evidence-based review. Mov Disord. 2002 07;17(S4):i–i. .
   Google Scholar
• Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008 Jan 30;23(2):183–189. quiz 313.
   PubMed Web of Science ®Google Scholar
• Schrag A. Quality of life and depression in Parkinson’s disease. J Neurol Sci. 2006 Oct 25;248(1–2):151–157.
   PubMed Web of Science ®Google Scholar
• Constantinescu R. Update on the use of pramipexole in the treatment of Parkinson’s disease. Neuropsychiatr Dis Treat. 2008 Apr;4(2):337–352. .
   PubMedGoogle Scholar
• Whitton AE, Reinen JM, Slifstein M, et al. Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. Brain. 2020 Feb 1;143(2):701–710.
   PubMedGoogle Scholar
• Willner P, Lappas S, Cheeta S, et al. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl). 1994 Aug;115(4):454–462. .
   PubMed Web of Science ®Google Scholar
• Maj J, Rogoz Z, Skuza G, et al. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm (Vienna). 1997 04; 104(4–5):525–533. .
   PubMed Web of Science ®Google Scholar
• Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11(2):58–65. .
   PubMed Web of Science ®Google Scholar
• Szegedi A, Hillert A, Wetzel H, et al. Pramipexole, a dopamine agonist, in major depression: antidepressant effects and tolerability in an open-label study with multiple doses. Clin Neuropharmacol. 1997;20:S36–S45.
   PubMed Web of Science ®Google Scholar
• Hori H, Kunugi H. The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial. ScientificWorldJournal. 2012;2012:372474.
   PubMedGoogle Scholar
• Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004 Mar;161(3):564–566.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004 Jul 1;56(1):54–60.
   PubMed Web of Science ®Google Scholar
• Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety. 2004;20(3):131–138. .
   PubMed Web of Science ®Google Scholar
• Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997 Jul;49(1):162–168.
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Koester J, Fruh B, et al. The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009 Jan;31(1):89–98. .
   PubMed Web of Science ®Google Scholar
• Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol. 2003 Jul;10(4):399–406. .
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, et al. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. 2005 Spring;17(2):214–220. .
   PubMed Web of Science ®Google Scholar
• Kano O. Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;4(4):707–710.
   Google Scholar
• Reichmann H, Odin P, Brecht HM, et al. Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole. In: Parvez H, Riederer P, editors. Oxidative stress and neuroprotection; 2006. Vol. 71. Vienna: Springer. DOI:10.1007/978-3-211-33328-0_2
   Google Scholar
• Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006 May;253(5):601–607. .
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Jun;9(6):573–580. .
   PubMed Web of Science ®Google Scholar
• Amara AW, Chahine LM, Videnovic A. Treatment of sleep dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2017 Jul;19(7):26. .
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011 Feb 15;26(3):399–406.
   PubMed Web of Science ®Google Scholar
• Schenck CH, Bundlie SR, Ettinger MG, et al. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986 Jun;9(2):293–308. .
   PubMed Web of Science ®Google Scholar
• Postuma RB, Gagnon JF, Bertrand JA, et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015 Mar 17;84(11):1104–1113.
   PubMed Web of Science ®Google Scholar
• Fantini ML, Gagnon JF, Filipini D, et al. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003 Nov 25;61(10):1418–1420.
   PubMed Web of Science ®Google Scholar
• Schmidt MH, Koshal VB, Schmidt HS. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med. 2006 Aug;7(5):418–423.
   PubMed Web of Science ®Google Scholar
• Sasai T, Inoue Y, Matsuura M. Effectiveness of pramipexole, a dopamine agonist, on rapid eye movement sleep behavior disorder. Tohoku J Exp Med. 2012 Mar;226(3):177–181.
   PubMed Web of Science ®Google Scholar
• Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013 Feb;19(2):153–157.
   PubMed Web of Science ®Google Scholar
• Kumru H, Iranzo A, Carrasco E, et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep. 2008 Oct;31(10):1418–1421.
   PubMed Web of Science ®Google Scholar
• Tan SM, Wan YM. Pramipexole in the treatment of REM sleep behaviour disorder: A critical review. Psychiatry Res. 2016 Sep;30(243):365–372. .
   Google Scholar
• Brown RG, Landau S, Hindle JV, et al. Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):803–809. .
   PubMed Web of Science ®Google Scholar
• Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996 Oct;57(10):449–454.
   PubMed Web of Science ®Google Scholar
• Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson’s disease? A retrospective case series. Mov Disord. 1999 01;14(1):155–157. .
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology. 2000 Oct 24;55(8):1216–1218.
   PubMed Web of Science ®Google Scholar
• Gilat M, Coeytaux Jackson A, Marshall NS, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson’s disease: a randomised controlled trial. Mov Disord. 2020 Feb;35(2):344–349. .
   PubMed Web of Science ®Google Scholar
• Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007 Apr;254(4):459–464.
   PubMed Web of Science ®Google Scholar
• Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology. 1997 Jul;49(1 Suppl 1):S58–62.
   PubMed Web of Science ®Google Scholar
• Ghorpade S, Tripathi R, Sonawane D, et al. Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats. J Basic Clin Physiol Pharmacol. 2011 Nov 22;22(4):109–114.
   PubMedGoogle Scholar
• Mavrikaki M, Schintu N, Nomikos GG, et al. Ropinirole regulates emotionality and neuronal activity markers in the limbic forebrain. Int J Neuropsychopharmacol. 2014 Dec;17(12):1981–1993. .
   PubMed Web of Science ®Google Scholar
• Dhir A, Kulkarni SK. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Brain Res Bull. 2007 Sep 14;74(1–3):58–65.
   PubMed Web of Science ®Google Scholar
• Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease. Mol Psychiatry. 2014 Mar;19(3):358–367. .
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007 Apr 3;68(14):1108–1115. .
   PubMed Web of Science ®Google Scholar
• Rektorova I, Balaz M, Svatova J, et al. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol. 2008 Sep-Oct;31(5):261–266. .
   PubMed Web of Science ®Google Scholar
• Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008 May 15;23(7):964–969. .
   PubMed Web of Science ®Google Scholar
• Kang SY, Ryu HS, Sunwoo MK, et al. Sleepiness and depression in Parkinson’s disease patients treated with ropinirole and levodopa. J Mov Disord. 2017 Sep;10(3):123–129. .
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2012 Jan;19(1):105–113. .
   PubMed Web of Science ®Google Scholar
• Reichmann H, Cooper J, Rolfe K, et al. Sleep duration and “on” time during different periods of the day and night in patients with advanced Parkinson’s disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis. 2011;2011:354760.
   PubMed Web of Science ®Google Scholar
• Dusek P, Buskova J, Ruzicka E, et al. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin Neuropharmacol. 2010 Jul;33(4):186–190. .
   PubMed Web of Science ®Google Scholar
• Winkelmann J, Allen RP, Hogl B, et al. Treatment of restless legs syndrome: evidence-based review and implications for clinical practice (Revised 2017)(section sign). Mov Disord. 2018 Jul;33(7):1077–1091. .
   PubMed Web of Science ®Google Scholar
• Jenner P. Parkinson’s disease: pathological mechanisms and actions of piribedil. J Neurol. 1992;239(Suppl 1):S2–8.
   PubMedGoogle Scholar
• Millan MJ. From the cell to the clinic: a comparative review of the partial D(2)/D(3)receptor agonist and alpha2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther. 2010 Nov;128(2):229–273.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rascol O. Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease. CNS Drugs. 2016 Aug;30(8):703–717. .
   PubMed Web of Science ®Google Scholar
• Lieberman AN, Shopsin B, Brun YL, et al. Studies on piribedil in Parkinsonism. Adv Neurol. 1975;9:399–407.
   PubMedGoogle Scholar
• Sweet RD, Wasterlain CG, McDowell FH. Piribedil, a dopamine agonist, in Parkinson’s disease. Clin Pharmacol Ther. 1974 Dec;16(6):1077–1082.
   PubMed Web of Science ®Google Scholar
• Feigenson JS, Sweet RD, McDowell FH. Piribedil: its synergistic effect in multidrug regimens for parkinsonism. Neurology. 1976 May;26(5):430–433.
   PubMed Web of Science ®Google Scholar
• Rascol O, Dubois B, Caldas AC, et al. Early piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN study. Mov Disord. 2006 Dec;21(12):2110–2115. .
   PubMed Web of Science ®Google Scholar
• Brocco M, Dekeyne A, Papp M, et al. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol. 2006 Nov;17(7):559–572. .
   PubMed Web of Science ®Google Scholar
• Mentenopoulos G, Katsarou Z, Bostantjopoulou S, et al. Piribedil therapy in Parkinson’s disease. Use of the drug in the retard form. Clin Neuropharmacol. 1989 Feb;12(1):23–28. .
   PubMed Web of Science ®Google Scholar
• Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol. 1992;239(Suppl 1):S28–34.
   PubMedGoogle Scholar
• Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013 May;136(Pt 5):1568–1577. .
   PubMedGoogle Scholar
• Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease. Mov Disord. 2006 Apr;21(4):500–509. .
   PubMed Web of Science ®Google Scholar
• Eggert K, Ohlwein C, Kassubek J, et al. Influence of the nonergot dopamine agonist piribedil on vigilance in patients with Parkinson disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol. 2014 Jul-Aug;37(4):116–122. .
   PubMed Web of Science ®Google Scholar
• Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology. 2005 Jul 26;65(2 Suppl 1):S3–5.
   PubMed Web of Science ®Google Scholar
• Wood M, Dubois V, Scheller D, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172(4):1124–1135. .
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Martinez-Martin P. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson’s disease: an overview. Expert Rev Neurother. 2013 Dec;13(12):1329–1342.
   PubMed Web of Science ®Google Scholar
• Valldeoriola F, Salvador A, Gomez-Arguelles JM, et al. The effects of transdermal rotigotine on non-motor symptoms of Parkinson’s disease: a multicentre, observational, retrospective, post-marketing study. Int J Neurosci. 2018 Apr;128(4):369–375. .
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011 Jan;26(1):90–99. .
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013 Jul;19(7):660–665. .
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Sringean J, Chaiwong S, et al. Rotigotine for nocturnal hypokinesia in Parkinson’s disease: quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor. Parkinsonism Relat Disord. 2017 Nov;44:124–128.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Nomoto M, Hasegawa K, et al. Rotigotine vs ropinirole in advanced stage Parkinson’s disease: a double-blind study. Parkinsonism Relat Disord. 2014 Dec;20(12):1388–1393. .
   PubMed Web of Science ®Google Scholar
• Pierantozzi M, Placidi F, Liguori C, et al. Rotigotine may improve sleep architecture in Parkinson’s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016 May;21:140–144.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang YC, Lan DM, et al. An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson’s disease. Sleep Breath. 2017 May;21(2):319–325. .
   PubMed Web of Science ®Google Scholar
• Calandra-Buonaura G, Guaraldi P, Doria A, et al. Rotigotine objectively improves sleep in Parkinson’s disease: an open-label pilot study with actigraphic recording. Parkinsons Dis. 2016;2016:3724148.
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Pinol G, Cardozo A, et al. Transdermal rotigotine improves sleep fragmentation in Parkinson’s disease: results of the multicenter, prospective SLEEP-FRAM study. Parkinsons Dis. 2015;2015:131508.
   PubMed Web of Science ®Google Scholar
• Ceballos-Baumann A, Hack HJ. Rotigotine transdermal patch in combination therapy for Parkinson’s disease–observations in routine clinical practice. Curr Med Res Opin. 2011 Oct;27(10):1899–1905.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Dioszeghy P, et al. Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: results from a 1-year, open-label extension of the RECOVER study. Basal Ganglia. 2012 07;2(2):79–85.
   Google Scholar
• Ghys L, Surmann E, Whitesides J, et al. Effect of rotigotine on sleep and quality of life in Parkinson’s disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother. 2011 Sep;12(13):1985–1998. .
   PubMed Web of Science ®Google Scholar
• Kim JM, Chung SJ, Kim JW, et al. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study. BMC Neurol. 2015 Feb 28;15:17. .
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang Y, Wu H, et al. Effects of rotigotine on REM sleep behavior disorder in Parkinson disease. J Clin Sleep Med. 2016 Oct 15;12(10):1403–1409.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Rotigotine transdermal patch: a review in restless legs syndrome. Drugs. 2016 Jul;76(10):1031–1040.
   PubMed Web of Science ®Google Scholar
• Serafini A, Lorenzut S, Gigli GL, et al. The use of rotigotine in the treatment of restless legs syndrome. Ther Adv Neurol Disord. 2010 Jul;3(4):241–248. .
   PubMedGoogle Scholar
• Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008 7;Jul(7):595–604.
   Google Scholar
• Giladi N, Fichtner A, Poewe W, et al. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J Neural Transm (Vienna). 2010 Dec;117(12):1395–1399. .
   PubMed Web of Science ®Google Scholar
• Rizos A, Martinez-Martin P, Odin P, et al. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson’s disease: an international multicenter study. Parkinsonism Relat Disord. 2014 Nov;20(11):1231–1235. .
   PubMed Web of Science ®Google Scholar
• Chung SJ, Asgharnejad M, Bauer L, et al. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease. Expert Opin Pharmacother. 2016 Aug;17(11):1453–1461. .
   PubMed Web of Science ®Google Scholar
• Antonini A, Bauer L, Dohin E, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015 Oct;22(10):1400–1407. .
   PubMed Web of Science ®Google Scholar
• Hauser RA, Slawek J, Barone P, et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease. BMC Neurol. 2016 Jun 7;16:90.
   PubMed Web of Science ®Google Scholar
• Wang HT, Wang L, He Y, et al. Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson’s disease: A meta-analysis of randomized placebo-controlled trials. J Neurol Sci. 2018 Oct 15;393:31–38. .
   PubMed Web of Science ®Google Scholar
• Rosa-Grilo M, Qamar MA, Taddei RN, et al. Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? NPJ Parkinsons Dis. 2017;3:28.
   PubMed Web of Science ®Google Scholar
• Timmermann L, Oehlwein C, Ransmayr G, et al. Patients’ perception of Parkinson’s disease-associated pain following initiation of rotigotine: a multicenter non-interventional study. Postgrad Med. 2017 Jan;129(1):46–54. .
   PubMed Web of Science ®Google Scholar
• Kassubek J, Chaudhuri KR, Zesiewicz T, et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014 Mar 6;14:42. .
   PubMed Web of Science ®Google Scholar
• Loddo G, Calandra-Buonaura G, Sambati L, et al. The treatment of sleep disorders in Parkinson’s disease: from research to clinical practice. Front Neurol. 2017;8:42.
   PubMed Web of Science ®Google Scholar
• Wailke S, Herzog J, Witt K, et al. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson’s disease. Eur J Neurol. 2011 Apr;18(4):590–596. .
   PubMed Web of Science ®Google Scholar
• Ohta K, Osada T. Rotigotine transdermal patch does not make Parkinson disease patients sleepy during daytime. Clin Neuropharmacol. 2015 Nov-Dec;38(6):231–235.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2007 Aug 15;22(11):1623–1629.
   PubMed Web of Science ®Google Scholar
• Carbone F, Djamshidian A, Seppi K, et al. Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019 Sep;33(9):905–918. .
   PubMed Web of Science ®Google Scholar
• Auffret M, Drapier S, Verin M. Pharmacological insights into the use of apomorphine in Parkinson’s disease: clinical relevance. Clin Drug Investig. 2018 Apr;38(4):287–312.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197–203. .
   PubMedGoogle Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015 Apr;30(4):510–516. .
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord. 2019 Mar;34(3):353–365. .
   PubMed Web of Science ®Google Scholar
• Li BD, Cui JJ, Song J, et al. Comparison of the efficacy of different drugs on non-motor symptoms of Parkinson’s disease: a network meta-analysis. Cell Physiol Biochem. 2018;45(1):119–130. .
   PubMedGoogle Scholar
• Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol. 2011 Apr;258(4):579–585. .
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, et al. Expert consensus group report on the use of apomorphine in the treatment of Parkinson’s disease–clinical practice recommendations. Parkinsonism Relat Disord. 2015 Sep;21(9):1023–1030. .
   PubMed Web of Science ®Google Scholar
• Borgemeester RW, Drent M, van Laar T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Parkinsonism Relat Disord. 2016 Feb;23:17–22.
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord. 2008 Jun 15;23(8):1130–1136.
   PubMed Web of Science ®Google Scholar
• Drapier S, Eusebio A, Degos B, et al. Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol. 2016 Jun;263(6):1111–1119. .
   PubMed Web of Science ®Google Scholar
• Borgemeester RWK, van Laar T. Continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with cognitive dysfunction: A retrospective long-term follow-up study. Parkinsonism Relat Disord. 2017 Dec;45:33–38.
   PubMed Web of Science ®Google Scholar
• Ellis C, Lemmens G, Parkes JD, et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord. 1997 04; 3(2):103–107. .
   PubMedGoogle Scholar
• Himeno E, Ohyagi Y, Ma L, et al. Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol. 2011 Feb;69(2):248–256. .
   PubMed Web of Science ®Google Scholar
• Steele JW, Gandy S. Apomorphine and Alzheimer Abeta: roles for regulated alpha cleavage, autophagy, and antioxidation? Ann Neurol. 2011 Feb;69(2):221–225.
   PubMed Web of Science ®Google Scholar
• Yarnall AJ, Lashley T, Ling H, et al. Apomorphine: a potential modifier of amyloid deposition in Parkinson’s disease? Mov Disord. 2016 May;31(5):668–675. .
   PubMed Web of Science ®Google Scholar
• Tribl GG, Sycha T, Kotzailias N, et al. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):181–185. .
   PubMed Web of Science ®Google Scholar
• Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand. 1999 Sep;100(3):163–167.
   PubMed Web of Science ®Google Scholar
• Isaacson S, Lew M, Ondo W, et al. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease. Mov Disord Clin Pract. 2017 Jan-Feb;4(1):78–83. .
   PubMed Web of Science ®Google Scholar
• Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord. 2000 Jan;15(1):167–169.
   PubMed Web of Science ®Google Scholar
• Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96–101. .
   PubMed Web of Science ®Google Scholar
• Dellapina E, Gerdelat-Mas A, Ory-Magne F, et al. Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2011 Jan;26(1):153–157. .
   PubMed Web of Science ®Google Scholar
• Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020 Feb;19(2):135–144. .
   PubMed Web of Science ®Google Scholar
• Hattori N, Mochizuki H, Hasegawa K, et al. Ropinirole patch versus placebo, ropinirole extended-release tablet in advanced Parkinson’s disease. Mov Disord. 2020 May 12. DOI:10.1002/mds.28071.
   Web of Science ®Google Scholar
• [Cited 2018 Dec 17]. https://www.luye.cn/lvye_en/view.php?id=1471.
   Google Scholar
• Dewey RB Jr., Maraganore DM, Ahlskog JE, et al. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson’s disease. Mov Disord. 1998 Sep;13(5):782–787. .
   PubMed Web of Science ®Google Scholar
• Grosset KA, Malek N, Morgan F, et al. Inhaled dry powder apomorphine (VR040) for ‘off ‘ periods in Parkinson’s disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand. 2013 Sep;128(3):166–171. .
   PubMed Web of Science ®Google Scholar
• Reichmann H. Dopamine agonist therapy in advanced Parkinson’s disease. J Mov Disord. 2009 May;2(1):10–13.
   PubMedGoogle Scholar
• Shulman LM, Minagar A, Rabinstein A, et al. The use of dopamine agonists in very elderly patients with Parkinson’s disease. Mov Disord. 2000 07;15(4):664–668.
   PubMed Web of Science ®Google Scholar
• Fitzsimmons PR, Blayney S, Mina-Corkill S, et al. Older participants are frequently excluded from Parkinson’s disease research. Parkinsonism Relat Disord. 2012 Jun;18(5):585–589. .
   PubMed Web of Science ®Google Scholar
• Borovac JA. Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016 Mar;89(1):37–47.
   PubMedGoogle Scholar
• Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine agonists and impulse control disorders: a complex association. Drug Saf. 2018 Jan;41(1):19–75. .
   PubMed Web of Science ®Google Scholar
• Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):685–689.
   PubMed Web of Science ®Google Scholar
• Bostwick JM, Hecksel KA, Stevens SR, et al. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc. 2009 Apr;84(4):310–316. .
   PubMed Web of Science ®Google Scholar
• Joutsa J, Martikainen K, Vahlberg T, et al. Impulse control disorders and depression in finnish patients with Parkinson’s disease. Parkinsonism Relat Disord. 2012 Feb;18(2):155–160. .
   PubMed Web of Science ®Google Scholar
• van Holst RJ, van den Brink W, Veltman DJ, et al. Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neurosci Biobehav Rev. 2010 Jan;34(1):87–107. .
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010 May;67(5):589–595. .
   PubMed Web of Science ®Google Scholar
• Weiss HD, Hirsch ES, Williams JR, et al. Detection of impulse control disorders in Parkinson disease patients. Neurologist. 2010 Nov;16(6):406–407. .
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006 Jul;63(7):969–973. .
   PubMedGoogle Scholar
• Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):840–844. .
   PubMed Web of Science ®Google Scholar
• Todorova A, Samuel M, Brown RG, et al. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years’ follow-up. Clin Neuropharmacol. 2015 Jul-Aug;38(4):132–134. .
   PubMed Web of Science ®Google Scholar
• Rizos A, Sauerbier A, Antonini A, et al. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016 Aug;23(8):1255–1261. .
   PubMed Web of Science ®Google Scholar
• Samuel M, Rodriguez-Oroz M, Antonini A, et al. Management of impulse control disorders in Parkinson’s disease: controversies and future approaches. Mov Disord. 2015 Feb;30(2):150–159. .
   PubMed Web of Science ®Google Scholar
• Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000 Oct;39(4):243–254.
   PubMed Web of Science ®Google Scholar
• Nicholas AP, Borgohain R, Chana P, et al. A randomized study of rotigotine dose response on ‘off’ time in advanced Parkinson’s disease. J Parkinsons Dis. 2014;4(3):361–373. .
   PubMedGoogle Scholar
• Oertel W, LeWitt P, Giladi N, et al. Treatment of patients with early and advanced Parkinson’s disease with rotigotine transdermal system: age-relationship to safety and tolerability. Parkinsonism Relat Disord. 2013 Jan;19(1):37–42. .
   PubMed Web of Science ®Google Scholar
• Nomoto M, Iwaki H, Kondo H, et al. Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials. J Neurol. 2018 Feb;265(2):253–265. .
   PubMed Web of Science ®Google Scholar
• Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2009 Mar;10(4):677–691.
   PubMed Web of Science ®Google Scholar
• Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol. 2009 Oct;8(10):929–937. .
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow? Neurology. 1999 Apr 12;52(6):1227–1229.
   PubMed Web of Science ®Google Scholar